| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
Novolog Innolet is owned by Novo Nordisk Inc.
Novolog Innolet contains Insulin Aspart Recombinant.
Novolog Innolet has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Novolog Innolet are:
- US5618913
- US5618913*PED
- US5866538
- US5866538*PED
- USRE41956
- USRE41956*PED
Novolog Innolet was authorised for market use on 31 October, 2013.
Novolog Innolet is available in injectable;subcutaneous dosage forms.
The generics of Novolog Innolet are possible to be released after 21 July, 2021.
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
NOVOLOG INNOLET family patents
